Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy. 2017;5:1264717.

Article  PubMed  Google Scholar 

Adair FE, Bagg HJ. Experimental and clinical studies on the treatment of cancer by Dichlorethylsulphide (Mustard Gas). Ann Surg.1931;93:190–9. https://oce-ovid-com.wmezproxy.wnmeds.ac.nz/article/00000658-193101000-00026/HTML.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haddow A. On the biological alkylating agents. Perspect Biol Med.1973;16:503–24. https://muse.jhu.edu/article/405762.

Article  CAS  PubMed  Google Scholar 

Schein CH. Repurposing approved drugs for cancer therapy. Br Med Bull.2021;137:13–27. https://academic.oup.com/bmb/article/137/1/13/6124816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;14:7.

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF. et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27. https://jamanetwork.com/journals/jamaoncology/fullarticle/2294966.

Article  PubMed  Google Scholar 

Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–9.

Article  PubMed  Google Scholar 

Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology—patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12:732–42. https://www.nature.com/articles/nrclinonc.2015.169.

Article  PubMed  Google Scholar 

Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62. https://doi.org/10.1257/jep.29.1.139.

Article  PubMed  Google Scholar 

Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. Lancet Oncol. 2020;21:664–70.

Article  CAS  PubMed  Google Scholar 

Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States. Cancer. 2010;116:3477–84. https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.25150.

Article  PubMed  Google Scholar 

Little A Beehive.govt.nz. 2022 [cited 2023 May 1]. Pharmac deal good news for New Zealanders. Available from: https://www.beehive.govt.nz/release/pharmac-deal-good-news-new-zealanders.

Main B, Csanadi M, Ozieranski P. Pricing strategies, executive committee power and negotiation leverage in New Zealand’s containment of public spending on pharmaceuticals. Health Econ Policy Law. 2022;17:348–65. https://www.cambridge.org/core/journals/health-economics-policy-and-law/article/pricing-strategies-executive-committee-power-and-negotiation-leverage-in-new-zealands-containment-of-public-spending-on-pharmaceuticals/573321297A6970CBB89C325D181637D8.

Article  PubMed  Google Scholar 

IQVIA. IQVIA. 2023 [cited 2023 May 1]. The global use of medicines 2023 Outlook to 2027. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2023.

Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200. https://www.nature.com/articles/nrd3681.

Article  CAS  PubMed  Google Scholar 

Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:1 [cited 2022 Dec 19]. Available from: https://www-nature-com.wmezproxy.wnmeds.ac.nz/articles/nbt.2786.

Pushpakom S. Chapter 1: Introduction and historical overview of drug repurposing opportunities. RSC Drug Discov Ser. 2022;2022:1–13. https://pubs.rsc.org/en/content/chapterhtml/2022/bk9781839163401-00001.

Google Scholar 

Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534:314–6.

Article  PubMed  Google Scholar 

Palve V, Liao Y, Remsing Rix LL, Rix U. Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Semin Cancer Biol. 2021;68:209–29.

Article  CAS  PubMed  Google Scholar 

Pantziarka P, Verbaanderd C, Huys I, Bouche G, Meheus L.Repurposing drugs in oncology: from candidate selection to clinical adoption.Semin Cancer Biol. 2021;68:186–91.

Article  CAS  PubMed  Google Scholar 

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G. et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol.2018;175:168–80. https://onlinelibrary.wiley.com/doi/full/10.1111/bph.13798.

Article  CAS  PubMed  Google Scholar 

Hong SJ, Li EC, Matusiak LM, Schumock GT. Spending on antineoplastic agents in the United States, 2011 to 2016. (2018);18:14. https://doi.org/10.1200/JOP.18.00069.

Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public–private partnership. Cancer Res. 2012;72:1055–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64.

Article  PubMed  PubMed Central  Google Scholar 

Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15:447–447.

PubMed  Google Scholar 

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18:41–58. https://www.nature.com/articles/nrd.2018.168.

Article  PubMed  Google Scholar 

Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013;7:753–66.

Google Scholar 

Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE. et al. The drug repurposing hub: a next-generation drug library and information resource. Nat Med. 2017;23:405–8. https://www.nature.com/articles/nm.4306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Himmelstein DS, Lizee A, Hessler C, Brueggeman L, Chen SL, Hadley D, et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife. 2017;22:6.

Mottini C, Napolitano F, Li Z, Gao X, Cardone L. Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets. Semin Cancer Biol. 2021;68:59–74.

Article  CAS  PubMed  Google Scholar 

Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014;19:637–44.

Article  PubMed  Google Scholar 

Parisi D, Adasme MF, Sveshnikova A, Bolz SN, Moreau Y, Schroeder M. Drug repositioning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. Comput Struct Biotechnol J. 2020;18:1043–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharm Ther. 2013;93:299–301.

Article  CAS  Google Scholar 

Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst. 2002;94:78–9.

Article  PubMed  Google Scholar 

Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–13.

Article  CAS  PubMed  Google Scholar 

Howell A, Howell SJ. Tamoxifen evolution. Br J Cancer. 2023;128:421–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Front Pharmacol. 2017;12:8.

Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013;12:1299–309.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:1–9.

Article  Google Scholar 

Wieder R, Adam N. Drug repositioning for cancer in the era of AI, big omics, and real-world data. Crit Rev Oncol Hematol. 2022;175:103730.

Article  PubMed  Google Scholar 

Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;17:3.

Lin WZ, Liu YC, Lee MC, Tang CT, Wu GJ, Chang YT, et al. From GWAS to drug screening: repurposing antipsychotics for glioblastoma. J Transl Med. 2022;20:70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baker S, Ali I, Silins I, Pyysalo S, Guo Y, Högberg J, et al. Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer. Bioinformatics. 2017;33:3973–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Detroja TS, Gil-Henn H, Samson AO. Text-mining approach to identify hub genes of cancer metastasis and potential drug repurposing to target them. J Clin Med. 2022;11:2130.

Article